For arthritis, iguratimod has been demonstrated to inhibit serum MMP-1 and MMP-3 of RA patients [27]; while in bleomycin-induced interstitial lung disease, iguratimod increased the level of MMP-9 of lung tissues [28]. Here, MMP1 is linked to arthritic joint disease.